Company intelligence / Profile preview

OncoQuest

Edmonton, Alberta, Canadaquestpharmatech.com ↗

Ownership: Private
Development stage: Phase 3

Overview

Lead product oregovomab has completed or is undergoing a confirmatory Phase IIb trial in ovarian cancer. Additional studies are ongoing or planned for pancreatic and ovarian cancers. The MUC1 program has completed a phase I trial in breast cancer. Next-generation IgE-based products are at the preclinical stage.

Therapeutic areas: Oncology
Modalities: Monoclonal antibodies (mAbs)Immunoglobulin E (IgE) antibodiesCombinatorial immunotherapy
Industry: Biotech

Drug pipeline

2 assets

oregovomab

1 more asset in the full pipeline.

Request access →

Partnerships

Hepalink (investor/partner)

Beyond the preview

Go deeper on OncoQuest.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OncoQuest.

Explore the full profile